China: Life sciences deals flourishing, but it's largely a domestic story

China's overall M&A activity cooled significantly in Q2 2020, but life sciences companies continue to be coveted. As trade tensions and protectionist policies elsewhere make it more difficult to attract foreign direct investment, domestic PE funds have stepped in to fill the void, looking to take advantage of a still-ripening opportunity.

Read More: China: Life sciences deals flourishing, but it's largely a domestic story


Download PDF Back To Listing
Loading data